Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 13;19(12):7233.
doi: 10.3390/ijerph19127233.

Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries

Fabrizio Bert  1 , Giacomo Scaioli  1 , Lorenzo Vola  1 , Davide Accortanzo  1 , Giuseppina Lo Moro  1 , Roberta Siliquini  1   2
Affiliations
Review

Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries

Fabrizio Bert et al. Int J Environ Res Public Health. .

Abstract

The need for an anti-COVID-19 booster dose posed an organizational challenge for health policy makers worldwide. Therefore, this study aimed to explore the health policies regarding the booster dose through an overview of recommendations issued in high-income countries. Between 10 November and 16 December 2021, the authors searched for state-level official documents about the offer of the booster dose, considering the 43 countries belonging to the European Union (EU) or the Organisation for Economic Co-operation and Development (OECD). Mainly due to the lack of English translation, 15 countries were excluded. A total of 135 documents were selected. Almost all the countries started administering the booster dose between September and November 2021. The most used products were mRNA vaccines, followed by Vaxzevria-AstraZeneca and Jcovden-Janssen/Johnson & Johnson. All countries established criteria to define categories of individuals to be vaccinated as a priority. A six/five-months interval was the main choice for general population vaccinated with mRNA vaccines, while shorter intervals were chosen for vulnerable individuals or other vaccines. Despite diversities related to the differences in health systems, economical resources, and population numbers, and the need to adapt all these factors to a massive vaccination campaign, a progressive convergence towards the same vaccination policies was highlighted.

Keywords: COVID-19; booster dose; health care policy; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Countries included in the study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tatar M., Wilson F.A. The Largest Vaccination Campaign in History: A Golden Opportunity for Bundling Public Health Interventions. J. Glob. Health. 2021;11:03076. doi: 10.7189/jogh.11.03076. - DOI - PMC - PubMed
    1. Ritchie H., Mathieu E., Rodés-Guirao L., Appel C., Giattino C., Ortiz-Ospina E., Hasell J., Macdonald B., Beltekian D., Roser M. Coronavirus Pandemic (COVID-19). Our World in Data. 2020. [(accessed on 8 January 2022)]. Available online: https://ourworldindata.org/coronavirus.
    1. Fiolet T., Kherabi Y., MacDonald C.-J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 Vaccines for Their Characteristics, Efficacy and Effectiveness against SARS-CoV-2 and Variants of Concern: A Narrative Review. Clin. Microbiol. Infect. 2022;28:202–221. doi: 10.1016/j.cmi.2021.10.005. - DOI - PMC - PubMed
    1. Zinatizadeh M.R., Zarandi P.K., Zinatizadeh M., Yousefi M.H., Amani J., Rezaei N. Efficacy of MRNA, Adenoviral Vector, and Perfusion Protein COVID-19 Vaccines. Biomed. Pharmacother. 2022;146:112527. doi: 10.1016/j.biopha.2021.112527. - DOI - PMC - PubMed
    1. Khandker S.S., Godman B., Jawad M.I., Meghla B.A., Tisha T.A., Khondoker M.U., Haq M.d.A., Charan J., Talukder A.A., Azmuda N., et al. A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines. 2021;9:1387. doi: 10.3390/vaccines9121387. - DOI - PMC - PubMed

Substances